VJOncology is committed to improving our service to you

ESMO Breast 2020 | Real-world: efficacy of everolimus + exemestane HR+, HER2- BC

VJOncology is committed to improving our service to you

Michael Gnant

Michael Gnant, MD, Vienna General Hospital, Vienna, Austria, discusses the STEPAUT study, a non-interventional study, evaluating the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter